Redox Biol: New molecules can relieve Alzheimer's disease.

6, 2020 /--- -- In a recent study, a candidate drug developed by Salk researchers that has been shown to delay the aging of brain cells has successfully reversed the memory loss shape of the hereditary Alzheimer's disease mouse model.
new study, published in the journal Redox Biology, also suggests that the drug, called CMS121, works by altering the metabolism of lipid molecules in brain cells.
, author of the study, said: "This is a more rigorous test of how effective this compound is in the therapeutic environment than our previous studies.
the success of this study, we are now conducting clinical trials.
(Photo: www.pixabay.com) Over the past few decades, Maher has studied how a chemical found in fruits and vegetables called fisetin improves memory and even prevents Alzheimer's disease in mice.
, the team synthesized different variants of fisetin and found that a variant called CMS121 was particularly effective in improving memory in animals and slowing brain cell degradation.
new study, Maher and colleagues tested the effects of CMS121 on mice developing Alzheimer's disease.
Maher's team gave mice CMS121 a day from the time they were nine months old.
were 12 months old, the researchers conducted a series of memory and behavioral tests on the mice.
who had been treated with Alzheimer's-like disease performed the same as healthy control animals, while untreated mice with the disease performed worse.
to better understand the effects of CMS121, the team compared the levels of different molecules in the brains of three groups of mice.
they found some differences in lipid levels (fat molecules that play a key role in cells) in mice with the disease compared to healthy mice and mice treated with CMS121.
the researchers pointed out in particular the difference in lipid peroxidation, which is the degradation of lipids and the resulting free-substate molecules that can continue to cause cell damage.
mice treated with Alzheimer's disease had higher lipid peroxidation levels than healthy mice or mice treated with CMS121.
not only confirms changes in lipid peroxidation in Alzheimer's disease, but the drug is actually normalizing these changes," said Gamze Ates, a postdoctoral researcher at the University of New South Wales.
researchers showed that CMS121 reduced the level of lipid-producing molecules called fatty acid synthesis enzymes (FASNs), which in turn reduced lipid peroxidation levels.
When the team analyzed FASN levels in brain samples of human patients who died of Alzheimer's disease, they found that the FASN protein levels in those patients were higher than similar older control groups in cognitive health, suggesting that FASN may have been the drug target for Alzheimer's disease.
the team's clinical trials, they hope other researchers will be able to explore other compounds that target FASN and lipid peroxidation, which can treat Alzheimer's disease.
(bioon.com) Source: New molybton changes Alzheimer's-like memory decline Original source: Gamze Ates et al, CMS121, a fatty acid synthase incedor, protects ad prolifaxed peroxidation and alzheimer's finds theagings in a transgenic mouse modeler's disease, Redox Biology (2020). DOI: 10.1016/j.redox.2020.101648.